Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 18/20 | 0.53 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL393114 | 0.89 | MAP2K1 (0.48) | MAP2K1MAP2K2HIF1ANPSR1RXFP1 | |
| SCHEMBL391996 | 0.78 | MAP2K1 (0.53) | MAP2K1MAP2K2ALOX15TSHR | |
| SCHEMBL27883696 | 0.75 | MAP2K1 (0.55) | MAP2K1MAP2K2ALOX15TSHR | |
| SCHEMBL394009 | 0.75 | MAP2K1 (0.55) | MAP2K1MAP2K2ALOX15TSHR | |
| SCHEMBL391465 | 0.73 | MAP2K1 (0.51) | MAP2K1MAP2K2ALOX15TSHR | |
| SCHEMBL387679 | 0.73 | MAP2K1 (0.52) | MAP2K1MAP2K2ALOX15TSHR | |
| SCHEMBL392179 | 0.72 | MAP2K1 (0.52) | MAP2K1MAP2K2 | |
| SCHEMBL392342 | 0.72 | MAP2K1 (0.47) | MAP2K1MAP2K2ALOX15TSHR | |
| SCHEMBL391162 | 0.71 | MAP2K1 (0.81) | MAP2K1MAP2K2 | |
| SCHEMBL392485 | 0.71 | MAP2K1 (0.81) | MAP2K1MAP2K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100063053-A1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063053-A1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | NRAS, BRAF, MAPK9 | MAP2K1 73/4885MAP2K2 63/4885HIF1A 1928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.